Asthma is a common chronic respiratory disease in children, contributing substantially to global morbidity. Vitamin D may influence asthma through immunomodulatory and anti-inflammatory effects, although clinical evidence remains inconsistent. This systematic review evaluated evidence published between 2015 and 2025 regarding vitamin D in preventing and managing pediatric asthma, distinguishing direct supplementation in children from maternal sufficiency during pregnancy. Following PRISMA 2020 guidelines, five databases were searched for studies published from January 2015 to September 2025. Two reviewers independently screened studies, extracted data, and assessed quality using Cochrane RoB 2.0 and Newcastle–Ottawa Scale tools. Eligible studies included randomized controlled trials and observational studies involving children aged 18 years or younger. Thirty-eight studies met the inclusion criteria. Vitamin D supplementation increased serum 25(OH)D levels and modestly reduced asthma exacerbations, particularly among children with baseline deficiency below 20 ng/mL. Some studies reported improvements in immune markers, including IL-6, IL-10, and TNF-α, while findings for lung function and daily asthma control remained inconsistent. Differences in study designs, dosing regimens, and baseline vitamin D status may explain these variations. Prenatal maternal vitamin D sufficiency demonstrated a distinct protective association with asthma development and recurrent wheezing in offspring. Supplementation was generally well tolerated at recommended doses. Overall, vitamin D may serve as an adjunctive intervention, particularly for deficient children, but universal supplementation cannot be recommended. Larger, long-term trials using standardized protocols are needed to establish optimal dosing and duration.